TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Share Price London S.E.
Equities
0RN3
JP3463000004
Pharmaceuticals
|
Market Closed -
Other stock markets
|
Pre-market 07:36:42 | |||
| 37.59 EUR | +6.79% |
|
25 | -33.48% |
| 06-06 | Former Takeda Employee Pleads Guilty to Defrauding Company | DJ |
| 06-06 | Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 4,264B 27.47B 25.22B 2,148B | Sales 2025 * | 4,252B 27.39B 25.15B 2,142B | Capitalization | 6,594B 42.48B 39.01B 3,322B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 928M 852M 72.58B | Net income 2025 * | 116B 750M 689M 58.67B | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.29B 22.31B 1,900B | Net Debt 2025 * | 4,224B 27.21B 24.99B 2,128B | EV / Sales 2025 * | 2.54 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
59.6
x | Employees | 49,095 |
| Yield 2024 |
4.49% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | -33.48% |
10 years
2.54
56.46
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 31/03/14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/01/22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 31/12/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 31/05/16 | |
Ian Clark
BRD | Director/Board Member | 62 | 31/12/18 |
Steven Gillis
BRD | Director/Board Member | 71 | 31/12/18 |
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
25/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,203
JPY
Average target price
4,768
JPY
Spread / Average Target
+13.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- 4502 Stock
- 0RN3 Stock
